

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/937,103	07/05/2002	Sandrine Lentsch Graf	01-1081	4719
	590 09/08/2004		EXAMINER	
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE			FORD, VANESSA L	
32ND FLOOR			ART UNIT	PAPER NUMBER
CHICAGO, IL	. 60606		1645	
			DATE MAILED: 09/08/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Advisory Action	09/937,103	GRAF ET AL.			
Advisory Action	Examiner	Art Unit			
	Vanessa L. Ford	1645			
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence address			
THE REPLY FILED 03 August 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.					
PERIOD FOR REPLY [check either a) or b)]					
a) The period for reply expires 3 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).					
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.					
2. The proposed amendment(s) will not be entered because:					
(a) X they raise new issues that would require further consideration and/or search (see NOTE below);					
(b) they raise the issue of new matter (see Note below);					
(c) \(\sum \) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or					
(d) they present additional claims without canceling a corresponding number of finally rejected claims.					
NOTE: see Advisory attachment.					
3. Applicant's reply has overcome the following rejection(s):					
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).					
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:					
6. The affidavit or exhibit will NOT be considered bed raised by the Examiner in the final rejection.	ause it is not directed SOLELY	to issues which were newly			
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we	(s) a)⊠ will not be entered or b ould be rejected is provided belo	□ will be entered and an wow or appended.	•		
The status of the claim(s) is (or will be) as follows:					
Claim(s) allowed: NONE					
Claim(s) objected to: <u>NONE</u> .					
Claim(s) rejected: <u>1-16</u> .					
Claim(s) withdrawn from consideration:					
8. The drawing correction filed on is a) appr	oved or b) disapproved by t	he Examiner.			
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)					
10.⊠ Other: <u>Advisory attachment.</u>					

Application/Control Number: 09/937,103

Art Unit: 1645

Advisory Action Attachment

1. Applicants amendment filed August 3, 2003 is acknowledged.

Applicants amendment is not entered because the claim as amended 2. would require further consideration and require new searches. As amended the claims are directed to a liquid vaccine composition comprising at least one antigen consisting of a polysaccharide bound to a carrier and further comprising trehalose, wherein the immunogenicity of the protein -linked polysaccharide in the composition is preserved to a greater extent over time as compared to the immunogenicity of the protein-linked polysaccharide alone and wherein the vaccine composition is maintained in a liquid state. The underlined portion of the claim is newly added. The newly added claim limitation has not been search or considered before the submission of the After Final Amendment. Additionally, the claims as amended would raise new 112 issues. New issues would include 112, first paragraph issues such as enablement for the claim limitation "...preserved for a greater extent over time...". New issues under 112, second paragraph, for example, it is unclear as to what Applicant intends by the recitation "greater extent over time?"

Page 3

Application/Control Number: 09/937,103

Art Unit: 1645

Rejections Maintained

3. The rejection of claims 1-4 under 35 U.S.C. 102(e) is maintained for the reasons set forth on pages 2-3, paragraph 4 of the Final Office Action.

Applicants arguments are directed to the newly amended claims, which have not been entered.

- 4. The rejection of claims 9-10 under 35 U.S.C. 102/103 is maintained for the reasons set forth on pages 4-5, paragraph 5 of the Final Office Action.

 Applicants arguments are directed to the newly amended claims, which have not been entered.
- 5. The rejection of claims 1-8 and 11-16 under 35 U.S.C. 103(a) is maintained for the reasons set forth on pages 5-7, paragraph 6 of the previous Office Action. Applicants arguments are directed to the newly amended claims which have not been entered.

Status of Claims

6. No claims are allowed.

Application/Control Number: 09/937,103

Art Unit: 1645

Conclusion

7. Any inquiry of the general nature or relating to the status of this general application should be directed to the Group receptionist whose telephone number is (703) 308–0196.

Papers relating to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. The faxing of such papers must conform with the notice published in the Office Gazette, 1096 OG 30 (November 15, 1989). Should applicant wish to FAX a response, the current FAX number for the Group 1600 is (703) 872-9306.

Any inquiry concerning this communication from the examiner should be directed to Vanessa L. Ford, whose telephone number is (571) 272-0857. The examiner can normally be reached on Monday — Friday from 9:00 AM to 6:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith, can be reached at (571) 272-0864.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov./. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Vanessa L. Ford Biotechnology Patent Examiner August 30, 2004

SUPERVISORY PATENT EXAMINED TECHNOLOGY CENTER ADDRESS